October 18, 2023 11:15 AM EDT

Ligand pays $30M upfront in royalty deal; Actym extends its Series A; Gero raises $6M

Jaimy Lee

Deputy Editor

Ligand acquires partial royalty rights to epilepsy candidate: Ligand said Wednesday that it’s paying $30 million upfront to Ovid Therapeutics as …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Ligand pays $30M upfront in royalty deal; Actym extends its Series A; Gero raises $6M

Jaimy Lee

Deputy Editor

Sign up to read this article for free.

Vertex’s non-opioid pill disappoints in mid-stage chronic pain study

David Epstein gets $140M for Ottimo's bifunctional take on hot PD-1xVEGF field

Roche’s Parkinson’s drug flunks second mid-stage trial

Novartis turns to BioAge for new targets based on longevity and exercise

Merck’s long-awaited obesity move is an oral GLP-1 from China

Sangamo strikes another brain-targeting AAV partnership, this time with Astellas

Lig­and pays $30M up­front in roy­al­ty deal; Ac­tym ex­tends its Se­ries A; Gero rais­es $6M

Jaimy Lee

Deputy Editor

Sign up to read this article for free.

more like this

Ver­tex’s non-opi­oid pill dis­ap­points in mid-stage chron­ic pain study

David Ep­stein gets $140M for Ot­ti­mo's bi­func­tion­al take on hot PD-1xVEGF field

Roche’s Parkin­son’s drug flunks sec­ond mid-stage tri­al

No­var­tis turns to BioAge for new tar­gets based on longevi­ty and ex­er­cise

Mer­ck’s long-await­ed obe­si­ty move is an oral GLP-1 from Chi­na

Sang­amo strikes an­oth­er brain-tar­get­ing AAV part­ner­ship, this time with Astel­las

Ligand pays $30M upfront in royalty deal; Actym extends its Series A; Gero raises $6M

Vertex’s non-opioid pill disappoints in mid-stage chronic pain study

David Epstein gets $140M for Ottimo's bifunctional take on hot PD-1xVEGF field

Roche’s Parkinson’s drug flunks second mid-stage trial

Novartis turns to BioAge for new targets based on longevity and exercise

Merck’s long-awaited obesity move is an oral GLP-1 from China

Sangamo strikes another brain-targeting AAV partnership, this time with Astellas